Monitor the company's first earnings report as a public company for guidance on revenue trajectory and pipeline progress. The IPO provides a cash runway but no revenue or profitability metrics were disclosed in this filing.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $25.00entry
- T+1 · 7mo ago +0.04%α −1.34% · $25.01
- T+5 · 6mo ago +3.60%α +1.62% · $25.90
- T+20 · 6mo ago +9.88%α +4.93% · $27.47
- T+60 · 4mo ago +89.88%α +87.14% · $47.47
Price Chart
How similar events traded
Executive Summary
Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross proceeds. Concurrently, the company adopted a restated certificate and bylaws with standard public-company governance provisions (classified board, supermajority voting, exclusive forum). This is a routine post-IPO administrative filing with no new financial data or operational updates.
Key Facts
- IPO closed on May 4, 2026, with 19,262,500 shares sold including full exercise of underwriter option
- IPO price: $18.00 per share
- Gross proceeds: $346.7 million before underwriting discounts and expenses
- Restated certificate increases authorized common stock to 400,000,000 shares and authorizes 5,000,000 shares of undesignated preferred stock
- New governance features: classified board, director removal only for cause with 75% supermajority vote, no stockholder action by written consent, exclusive forum provisions
Financial Impact
IPO raised $346.7 million in gross proceeds; net proceeds will be lower after underwriting discounts and expenses (not specified)
Risk Factors
- Pre-revenue biotech with no approved products or disclosed financial performance
- Governance changes (classified board, supermajority requirements) reduce stockholder influence and could deter activist investors
- Potential dilution from authorized but unissued preferred stock
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-203988 |
| Document: d149100dex31.htm | 0001193125-26-203988 |
| Document: d149100d8k.htm | 0001193125-26-203988 |
| Document: 0001193125-26-203988-index-headers.html | 0001193125-26-203988 |
| Document: 0001193125-26-203988-index.html | 0001193125-26-203988 |
| Document: 0001193125-26-203988.txt | 0001193125-26-203988 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Viewing Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers